Standardized uptake values of68Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumors

Journal of Nuclear Medicine

Volumn 51, Issue 3, 2010, Pages 353-359

  Campana, Davide ^a   Ambrosini, Valentina ^a   Pezzilli, Raffaele ^a   Fanti, Stefano ^a   Labate, Antonio Maria Morselli ^a   Santini, Donatella ^a   Ceccarelli, Claudio ^a   Nori, Francesca ^a   Franchi, Roberto ^a   Corinaldesi, Roberto ^a   Tomassetti, Paola ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

68Ga DOTANOC; Neuroendocrine tumors; Positron emission tomography; Receptors; Somatostatin

Indexed keywords

[1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID] 1 NAL3 OCTREOTIDE GA 68; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 2; TRACER; UNCLASSIFIED DRUG; 68GA TETRAAZACYCLODODECANE TETRAACETIC ACID NAL(3) OCTREOTIDE; 68GA-TETRAAZACYCLODODECANE TETRAACETIC ACID-NAL(3)-OCTREOTIDE; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 77950345549     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.066662     Document Type: Article

References (30)

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
2. Soreide JA, van Heerden JA, Thompson GB, Schleck C, Ilstrup DM, Churchward M. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg. 2000;24:1431-1436.
3. Hellman P, Lundstrom T, Ohrvall U, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002;26:991-997. (Pubitemid 36920298)
4. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083-1092. (Pubitemid 41815799)
5. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16:1806-1810. (Pubitemid 41631244)
6. Tomassetti P, Campana D, Piscitelli L, et al. Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology. 2006;83:380-386. (Pubitemid 44729795)
7. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757-762. (Pubitemid 47497934)
8. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. (Pubitemid 44451313)
9. 68Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751-1757.
10. 18F-FDG. Cancer. 2008;112:2447-2455.
11. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431-1438.
12. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347. (Pubitemid 37247950)
13. Wild D, Macke HR, Waser B, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724. (Pubitemid 40897499)
14. Hoskin PJ, Chin Y, Wong W, Rojas A. The value of SUV in FDG PET for lymphoma [abstract]. Clin Oncol (R Coll Radiol). 2007;19(3, suppl):S32.
15. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUVon PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2009;21:1008-1015.
16. Sun JS, Park KJ, Sheen SS, et al. Clinical usefulness of the fluorodeoxyglucose (FDG)-PET maximal standardized uptake value (SUV) in combination with CT features for the differentiation of adenocarcinoma with a bronchioloalveolar carcinoma from other subtypes of non-small cell lung cancers. Lung Cancer. 2009:66:205-210.
17. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol. 2008;19:282-288.
18. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 1990;50:7057-7061. (Pubitemid 20361113)
19. 68Ga for medical application. J Nucl Med. 2007;48:1741-1748.
20. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771-1777. (Pubitemid 29523568)
21. Pezzilli R, Billi P, Miniero R, et al. Serum interleukin-6, interleukin-8, and beta 2-microglobulin in early assessment of severity of acute pancreatitis: comparison with serum C-reactive protein. Dig Dis Sci. 1995;40:2341-2348.
22. Khan MU, Khan S, El-Refaie S, Win Z, Rubello D, Al-Nahhas A. Clinical indications for gallium-68 positron emission tomography imaging. Eur J Surg Oncol. 2009:35:561-567.
23. 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:48-52.
24. O'Toole D, Saveanu A, Couvelard A, et al. The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006;155:849-857. (Pubitemid 46040624)
25. Asnacios A, Courbon F, Rochaix P, et al. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J Clin Oncol. 2008;26:963-970. (Pubitemid 351398091)
26. Wulbrand U, Wied M, Zofel P, Goke B, Arnold R, Fehmann H. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. Eur J Clin Invest. 1998;28:1038-1049. (Pubitemid 29050140)
27. Jais P, Terris B, Ruszniewski P, et al. Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest. 1997;27:639-644. (Pubitemid 27368293)
28. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47:223-233. (Pubitemid 46780886)
29. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475. (Pubitemid 34591729)
30. 177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.